Clinical jobs provider Bristol-Myers Squibb (BMS) has exceeded expectations in the second quarter of 2011, thanks to the success of its product launches and clinical research.
The company is raising its guidance for the full year after seeing a 14 per cent increase in sales year on year, achieving a total of $5.4 billion (£3.3 billion) for the quarter.
This was attributable to strong global demand for drugs such as Plavix, Onglyza, Orencia and Sprycel, while newly launched therapies such as Yervoy and Kombiglyze made encouraging debuts.
It was also able to publish positive clinical trial data on drugs such as dapagliflozin and Eliquis, and gain regulatory approval for a number of important new compounds.
Lamberto Andreotti, chief executive officer at BMS, said: "This performance demonstrates the success of our biopharmaceutical strategy in delivering short-term results and in positioning the company for the future."
Earlier this month, BMS received approval from the European Commission for Yervoy as an advanced melanoma therapy, based on positive clinical research data.